Abstract
Simple SummaryUp to 85% of patients with colorectal liver metastases develop distant intrahepatic recurrence after curative intent local treatment. (Inter)national guidelines and scientific societies consider repeat local treatment, comprising repeat thermal ablation and/or repeat resection, the standard of care to treat recurrent new colorectal liver metastases. This systematic review and meta-analysis assessed the potential additive value of neoadjuvant chemotherapy before repeat local treatment. The addition of neoadjuvant chemotherapy prior to repeat local treatment was suggested by merely all authors, though supporting evidence is lacking. The results do not substantiate the routine use of neoadjuvant chemotherapy. We are currently constructing a phase III randomized controlled trial directly comparing upfront repeat local treatment with neoadjuvant chemotherapy followed by repeat local treatment (COLLISION RELAPSE trial).The additive value of neoadjuvant chemotherapy (NAC) prior to repeat local treatment of patients with recurrent colorectal liver metastases (CRLM) is unclear. A systematic search was performed in PubMed, Embase, Web of Science, and an additional search in Google Scholar to find articles comparing repeat local treatment by partial hepatectomy and/or thermal ablation with versus without NAC. The search included randomized trials and comparative observational studies with univariate/multivariate analysis and/or matching as well as (inter)national guidelines assessed using the AGREE II instrument. The search identified 21,832 records; 172 were selected for full-text review; 20 were included: 20 comparative observational studies were evaluated. Literature to evaluate the additive value of NAC prior to repeat local treatment was limited. Outcomes of NAC were often reported as subgroup analyses and reporting of results was frequently unclear. Assessment of the seven studies that qualified for inclusion in the meta-analysis showed conflicting results. Only one study reported a significant difference in overall survival (OS) favoring NAC prior to repeat local treatment. However, further analysis revealed a high risk for residual bias, because only a selected group of chemo-responders qualified for repeat local treatment, disregarding the non-responders who did not qualify. All guidelines that specifically mention recurrent disease (3/3) recommend repeat local treatment; none provide recommendations about the role of NAC. The inconclusive findings of this meta-analysis do not support recommendations to routinely favor NAC prior to repeat local treatment. This emphasizes the need to investigate the additive value of NAC prior to repeat local treatment of patients with recurrent CRLM in a future phase 3 randomized controlled trial (RCT).
Highlights
Colorectal cancer (CRC) is the second most common cancer type in women and the third most common in men; it represents about 10% of the annual global cancer incidence [1]
PubMed, Embase.com, and Clarivate Analytics/Web of Science Core Collection were systematically searched from inception up to 29 October 2020 for publications reporting on the outcomes of neoadjuvant chemotherapy (NAC) before local treatment of recurrent colorectal liver metastases (CRLM)
The following PICO question was used for the search strategy and inclusion criteria: p: patients with recurrent CRLM; (I) intervention: neoadjuvant chemotherapy (NAC) before repeat local treatment; (C) comparison: repeat local treatment alone; (O) outcome: the critical endpoint was overall survival (OS), important endpoints were disease-free survival (DFS), complications, quality of life (QoL), and cost-effectiveness
Summary
Colorectal cancer (CRC) is the second most common cancer type in women and the third most common in men; it represents about 10% of the annual global cancer incidence [1]. The prognosis of CRC patients largely depends on the presence of distant metastasis, the liver being the most frequently involved organ. Up to 50% of patients develop colorectal liver metastases (CRLM) during the course of disease [2,3,4,5,6,7]. One-fifth of patients who develop CRLM are eligible for curative intent local treatment options, such as partial hepatectomy or thermal ablation (radiofrequency ablation, RFA; microwave ablation; MWA) [3,11,12,13,14,15,16,17]. The five-year OS for upfront resectable and/or ablatable disease nowadays reaches 44–58% [18,19,20,21,22,23,24,25,26,27,28] and even up to 33% for an increasing number of patients with initially unresectable and unablatable disease who are successfully downstaged after induction chemotherapy [12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
